10 November 2022 
EMA/862231/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Plavix 
clopidogrel  
On  10  November 2022,  the  Committee for  Medicinal Products  for Human  Use  (CHMP)  adopted  a positive 
opinion  recommending a  change  to  the  terms  of  the  marketing  authorisation  for  the  medicinal  product 
Plavix. The marketing authorisation holder for this  medicinal product is sanofi -aventis groupe. 
The  CHMP  adopted  a  change  to  the  existing  indication  to  include  the  secondary  prevention  of 
atherothrombotic  events  in  patients  with  ST  segment  elevation  acute  myocardial  infarction  (STEMI)  
undergoing percutaneous coronary intervention (PCI) 
For information, the full indications  for Plavix will  be as follows 2: 
       Secondary prevention of atherothrombotic events 
       Clopidogrel is indicated in: 
•  Adult  patients  suffering  from  myocardial  infarction  (from  a  few  days  until   less  than 
35 days),  ischemic  stroke  (from  7 days  until  less  than  6 months)  or  established 
peripheral arterial disease. 
•  Adult patients  suffering from acute coronary syndrome: 
-  Non-ST  segment elevation acute coronary syndrome (unstable angina  or non -Q-wave 
myocardial  infarction),  including  patients  undergoing  a  stent  placement  following 
percutaneous coronary intervention, in combination with  acetylsalicylic acid (ASA).  
- 
ST segment elevation acute myocardial infarction, in combination with  ASA in patients 
undergoing  percutaneous 
coronary 
intervention 
(including  patients 
undergoing  a  stent  placement)  or  medically  treated  patients  eligible  for 
thrombolytic/fibrinolytic therapy.  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European  Union    
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
In patients  with  moderate to high-risk  Transient Ischemic Attack  (TIA) or minor Ischemic Stroke  
(IS) Clopidogrel in combination with  ASA is indicated in: 
- Adult patients with moderate to high-risk TIA (ABCD23 score ≥4) or minor IS (NIHSS 4 ≤3) within 
24 hours of either the  TIA or IS event.   
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation  
In adult  patients  with  atrial fibrillation  who  have at  least one risk factor for vascular events, are 
not  suitable  for  treatment  with  Vitamin  K  antagonists  (VKA)  and  who  have a  low  bleeding  risk, 
clopidogrel  is  indicated  in  combination  with  ASA  for  the  prevention  of  atherothrombotic  and 
thromboembolic events, including stroke. 
For further information please refer to section 5.1. 
Detailed recommendations for the use of this  product will be described in the updated summary of product 
characteristics (SmPC), which  will  be published in  the revised European public  assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
3 Age, Blood pressure, Clinical features, Durati on, and Diabetes mellitus diagnosis 
4 National Institutes of Health Stroke Scale  
Plavix  
EMA/862231/2022 
Page 2/2 
 
 
 
 
 
 
 
 
